BACKGROUND: We report the first-in-human safety and immunogenicity assessment of a prototype hexon chimeric adenovirus (Ad) serotype 5 (Ad5) vector containing the hexon hypervariable regions of Ad serotype 48 (Ad48) and expressing human immunodeficiency virus (HIV) type 1 EnvA. METHODS:Forty-eight Ad5 and Ad48 seronegative, HIV-uninfected subjects were enrolled in a randomized, double-blind, placebo-controlled, dose escalation phase 1 study. Four groups of 12 subjects received 10(9) to 10(11) viral particles (vp) of the Ad5HVR48.EnvA.01 vaccine (n = 10 per group) or placebo (n = 2 per group) at week 0 or weeks 0, 4, and 24. Safety and immunogenicity were assessed. RESULTS:Self-limited reactogenicity was observed after the initial immunization in the highest (10(11) vp) dose group. Responses in vaccinees included Ad48neutralizing antibody (nAb) titers higher than Ad5 nAb titers, EnvA-specific enzyme-linked immunosorbent assay titers, and EnvA-specific enzyme-linked immunospot assay responses, and these responses generally persisted at week 52. At week 28 in the 10(9), 10(10), and 10(11) vp 3-dose groups, geometric mean EnvA enzyme-linked immunosorbent assay titers were 5721, 10 929, and 3420, respectively, and Ad48 nAb titers were a median of 1.7-fold higher than for Ad5. CONCLUSIONS: Ad5HVR48.ENVA.01 was safe, well tolerated, and immunogenic at all doses tested. Vector-elicited nAb responses were greater for Ad48 than Ad5, confirming that Ad-specific nAbs in humans are primarily, but not exclusively, directed against the hexon hypervariable regions. Clinical Trials Registration. NCT00695877.
RCT Entities:
BACKGROUND: We report the first-in-human safety and immunogenicity assessment of a prototype hexon chimeric adenovirus (Ad) serotype 5 (Ad5) vector containing the hexon hypervariable regions of Ad serotype 48 (Ad48) and expressing human immunodeficiency virus (HIV) type 1 EnvA. METHODS: Forty-eight Ad5 and Ad48 seronegative, HIV-uninfected subjects were enrolled in a randomized, double-blind, placebo-controlled, dose escalation phase 1 study. Four groups of 12 subjects received 10(9) to 10(11) viral particles (vp) of the Ad5HVR48.EnvA.01 vaccine (n = 10 per group) or placebo (n = 2 per group) at week 0 or weeks 0, 4, and 24. Safety and immunogenicity were assessed. RESULTS: Self-limited reactogenicity was observed after the initial immunization in the highest (10(11) vp) dose group. Responses in vaccinees included Ad48 neutralizing antibody (nAb) titers higher than Ad5 nAb titers, EnvA-specific enzyme-linked immunosorbent assay titers, and EnvA-specific enzyme-linked immunospot assay responses, and these responses generally persisted at week 52. At week 28 in the 10(9), 10(10), and 10(11) vp 3-dose groups, geometric mean EnvA enzyme-linked immunosorbent assay titers were 5721, 10 929, and 3420, respectively, and Ad48 nAb titers were a median of 1.7-fold higher than for Ad5. CONCLUSIONS: Ad5HVR48.ENVA.01 was safe, well tolerated, and immunogenic at all doses tested. Vector-elicited nAb responses were greater for Ad48 than Ad5, confirming that Ad-specific nAbs in humans are primarily, but not exclusively, directed against the hexon hypervariable regions. Clinical Trials Registration. NCT00695877.
Authors: Karin Loré; William C Adams; Menzo J E Havenga; Melissa L Precopio; Lennart Holterman; Jaap Goudsmit; Richard A Koup Journal: J Immunol Date: 2007-08-01 Impact factor: 5.422
Authors: Shawn M Sumida; Diana M Truitt; Angelique A C Lemckert; Ronald Vogels; Jerome H H V Custers; Marylyn M Addo; Shahin Lockman; Trevor Peter; Fred W Peyerl; Michael G Kishko; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Myron Essex; Bruce D Walker; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch Journal: J Immunol Date: 2005-06-01 Impact factor: 5.422
Authors: Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para Journal: J Infect Dis Date: 2005-01-27 Impact factor: 5.226
Authors: Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert Journal: N Engl J Med Date: 2013-10-07 Impact factor: 91.245
Authors: Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim Journal: N Engl J Med Date: 2009-10-20 Impact factor: 91.245
Authors: Dan H Barouch; Kathryn E Stephenson; Erica N Borducchi; Kaitlin Smith; Kelly Stanley; Anna G McNally; Jinyan Liu; Peter Abbink; Lori F Maxfield; Michael S Seaman; Anne-Sophie Dugast; Galit Alter; Melissa Ferguson; Wenjun Li; Patricia L Earl; Bernard Moss; Elena E Giorgi; James J Szinger; Leigh Anne Eller; Erik A Billings; Mangala Rao; Sodsai Tovanabutra; Eric Sanders-Buell; Mo Weijtens; Maria G Pau; Hanneke Schuitemaker; Merlin L Robb; Jerome H Kim; Bette T Korber; Nelson L Michael Journal: Cell Date: 2013-10-24 Impact factor: 41.582
Authors: Mario Roederer; Brandon F Keele; Stephen D Schmidt; Rosemarie D Mason; Hugh C Welles; Will Fischer; Celia Labranche; Kathryn E Foulds; Mark K Louder; Zhi-Yong Yang; John-Paul M Todd; Adam P Buzby; Linh V Mach; Ling Shen; Kelly E Seaton; Brandy M Ward; Robert T Bailer; Raphael Gottardo; Wenjuan Gu; Guido Ferrari; S Munir Alam; Thomas N Denny; David C Montefiori; Georgia D Tomaras; Bette T Korber; Martha C Nason; Robert A Seder; Richard A Koup; Norman L Letvin; Srinivas S Rao; Gary J Nabel; John R Mascola Journal: Nature Date: 2013-12-18 Impact factor: 49.962
Authors: Julio Alonso-Padilla; Tibor Papp; Győző L Kaján; Mária Benkő; Menzo Havenga; Angelique Lemckert; Balázs Harrach; Andrew H Baker Journal: Mol Ther Date: 2015-10-19 Impact factor: 11.454
Authors: Michelle C Crank; Eleanor M P Wilson; Laura Novik; Mary E Enama; Cynthia S Hendel; Wenjuan Gu; Martha C Nason; Robert T Bailer; Gary J Nabel; Adrian B McDermott; John R Mascola; Richard A Koup; Julie E Ledgerwood; Barney S Graham Journal: PLoS One Date: 2016-11-15 Impact factor: 3.240
Authors: Dafni Chondronasiou; Tracy-Jane T H D Eisden; Anita G M Stam; Qiana L Matthews; Mert Icyuz; Erik Hooijberg; Igor Dmitriev; David T Curiel; Tanja D de Gruijl; Rieneke van de Ven Journal: Vaccines (Basel) Date: 2018-07-18
Authors: Huma Qureshi; Meritxell Genescà; Linda Fritts; Michael B McChesney; Marjorie Robert-Guroff; Christopher J Miller Journal: PLoS One Date: 2014-09-09 Impact factor: 3.240
Authors: Natalia V Eremina; Vasily I Kazey; Sergey V Mishugin; Roman V Leonenkov; Dmitry Y Pushkar; Vadim L Mett; Andrei V Gudkov Journal: Oncotarget Date: 2020-04-07